Loading...
XJPX
3183
Market cap230mUSD
Dec 05, Last price  
1,288.00JPY
1D
-0.85%
1Q
-2.87%
Jan 2017
27.65%
IPO
236.73%
Name

Win-Partners Co Ltd

Chart & Performance

D1W1MN
XJPX:3183 chart
P/E
17.72
P/S
0.44
EPS
72.69
Div Yield, %
3.88%
Shrs. gr., 5y
-0.03%
Rev. gr., 5y
4.75%
Revenues
81.41b
+5.64%
28,050,860,00028,127,098,00029,987,165,00029,258,841,00032,957,462,00033,912,558,00049,826,000,00050,558,000,00054,147,438,00057,760,490,00062,832,480,00069,775,788,00064,537,869,00062,123,939,00066,391,940,00070,854,470,00077,064,194,00081,410,300,000
Net income
2.02b
+9.98%
940,129,000820,954,000902,297,000854,006,000955,316,000960,126,0001,840,000,0001,690,000,0002,111,656,0002,141,028,0003,005,542,0002,640,829,0001,872,588,0001,540,597,0001,831,893,0002,047,262,0001,835,759,0002,019,052,000
CFO
2.06b
-32.38%
823,827,000866,216,0001,707,479,000616,405,000596,146,0001,737,691,0002,892,000,000-312,000,0002,294,373,0003,386,004,0001,343,723,0002,289,981,0003,219,666,0001,850,516,0002,622,058,000445,148,0003,043,527,0002,058,002,000
Dividend
Mar 30, 202653 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

WIN-Partners Co., Ltd., through its subsidiaries, distributes medical devices to medical institutions primarily in Japan. The company offers percutaneous transluminal coronary angioplasty balloon catheters, drug-eluting stents, and intravascular ultrasound catheters; pacemakers, implantable cardioverter defibrillators, cardiac resynchronization therapy defibrillators, and ablation catheters; and stent grafts, transcatheter heart valves, and mechanical heart valves. It also provides peripheral vascular stents, carotid artery stents, and embolic coils; and insulin pumps, as well as continuous glucose monitoring and magnetic resonance imaging equipment. The company was founded in 1973 and is headquartered in Tokyo, Japan.
URL
https://www.win-partners.co.jp/
IPO date
Apr 01, 2013
Employees
609
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT